Success Metrics

Clinical Success Rate
80.0%

Based on 52 completed trials

Completion Rate
80%(52/65)
Active Trials
5(7%)
Results Posted
54%(28 trials)
Terminated
13(17%)

Phase Distribution

Ph not_applicable
1
1%
Ph phase_3
4
5%
Ph phase_2
25
33%
Ph early_phase_1
1
1%
Ph phase_1
43
57%

Phase Distribution

44

Early Stage

25

Mid Stage

4

Late Stage

Phase Distribution74 total trials
Early Phase 1First-in-human
1(1.4%)
Phase 1Safety & dosage
43(58.1%)
Phase 2Efficacy & side effects
25(33.8%)
Phase 3Large-scale testing
4(5.4%)
N/ANon-phased studies
1(1.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

74.3%

52 of 70 finished

Non-Completion Rate

25.7%

18 ended early

Currently Active

5

trials recruiting

Total Trials

75

all time

Status Distribution
Active(5)
Completed(52)
Terminated(18)

Detailed Status

Completed52
Terminated13
Withdrawn5
Recruiting3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
75
Active
5
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.4%)
Phase 143 (58.1%)
Phase 225 (33.8%)
Phase 34 (5.4%)
N/A1 (1.4%)

Trials by Status

active_not_recruiting23%
completed5269%
withdrawn57%
recruiting34%
terminated1317%

Recent Activity

5 active trials
Showing 5 of 75
recruitingphase_1

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

NCT06963346
completedphase_3

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

NCT03703375
completedphase_2

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516
terminatedphase_1

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700
completedphase_1

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

NCT02783625
View all 75 trials

Clinical Trials (75)

Showing 20 of 75 trialsScroll for more
NCT06963346Phase 1

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Recruiting
NCT03703375Phase 3

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Completed
NCT02232516Phase 2

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Completed
NCT03547700Phase 1

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Terminated
NCT02783625Phase 1

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

Completed
NCT03593018Phase 3

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

Completed
NCT01846390Phase 1

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

Completed
NCT04447027Phase 1

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Completed
NCT04747236Phase 2

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

Recruiting
NCT03278782Phase 1

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

Active Not Recruiting
NCT02512172Phase 1

A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer

Completed
NCT02393794Phase 1

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Active Not Recruiting
NCT04257448Phase 1

Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer

Completed
NCT02512497Phase 1

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Completed
NCT03432741Phase 1

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Terminated
NCT01938833Phase 1

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Terminated
NCT03041012Phase 2

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

Completed
NCT02616965Phase 1

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Completed
NCT01638533Phase 1

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Completed
NCT04774068Phase 1

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

Completed

Drug Details

Intervention Type
DRUG
Total Trials
75